Cargando…

Plasma brain natriuretic peptide is a biomarker for screening ischemic cerebral small vessel disease in patients with hypertension

Plasma brain natriuretic peptide (BNP), a diagnostic marker of cardiovascular diseases, has been previously linked to cerebrovascular diseases. Our goal was to determine whether plasma BNP level is helpful for identifying high-risk individuals who are likely to present with the 3 main subtypes of ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Weimin, Chen, Yan, Lei, Da, Zhang, Yanan, Weng, Xiuhong, Zhou, Yuliang, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392776/
https://www.ncbi.nlm.nih.gov/pubmed/30170428
http://dx.doi.org/10.1097/MD.0000000000012088
_version_ 1783398549983068160
author Wei, Weimin
Chen, Yan
Lei, Da
Zhang, Yanan
Weng, Xiuhong
Zhou, Yuliang
Zhang, Li
author_facet Wei, Weimin
Chen, Yan
Lei, Da
Zhang, Yanan
Weng, Xiuhong
Zhou, Yuliang
Zhang, Li
author_sort Wei, Weimin
collection PubMed
description Plasma brain natriuretic peptide (BNP), a diagnostic marker of cardiovascular diseases, has been previously linked to cerebrovascular diseases. Our goal was to determine whether plasma BNP level is helpful for identifying high-risk individuals who are likely to present with the 3 main subtypes of cerebral small vessel diseases (CSVDs), namely, white matter lesions, lacunar infarcts, and cerebral microbleeds, on magnetic resonance imaging (MRI) in patients with hypertension. Three hundred forty-six consecutive hypertensive patients presenting at our cardiology or neurology clinic were investigated. Plasma BNP level was measured by chemiluminescent microparticle immunoassay. The presence of CSVD was assessed by 1.5-T brain MRI. Multivariate linear regression was used to determine whether individual or combined MRI-defined CSVD subtypes were associated with BNP level, after adjustment for several covariates. The mean age of patients was 69.1 ± 9.8 years, and 44.2% were female. The highest quartile BNP group was positively associated with advanced age, female sex, clinically manifesting cardiac diseases, and ischemic CSVD (white matter lesions and lacunar infarcts) and no association with cerebral microbleeds. According to multivariate linear regression, white matter lesions [β = 0.722; 95% confidence interval (95% CI), 0.624–0.819] and lacunar infarcts (β = 0.635; 95% CI, 0.508–0.762) were independently associated with BNP level, even after controlling for vascular risk factors and clinically manifesting cardiac diseases. Combined white matter lesions and lacunar infarcts were more strongly associated with BNP level than each subtype alone. With the cutoff value of 106.4 pg/mL, BNP level had a sensitivity, a specificity, and an area under the curve of 95.2%, 64.9%, and 0.799, respectively, for white matter lesions, whereas the values were 143.0 pg/mL, 81.6%, 73.5%, and 0.848, respectively, for lacunar infarcts. Plasma BNP level, which is independently correlated with individual or combined white matter lesions and lacunar infarcts, is a useful molecular marker for identifying ischemic CSVD in patients with hypertension.
format Online
Article
Text
id pubmed-6392776
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-63927762019-03-15 Plasma brain natriuretic peptide is a biomarker for screening ischemic cerebral small vessel disease in patients with hypertension Wei, Weimin Chen, Yan Lei, Da Zhang, Yanan Weng, Xiuhong Zhou, Yuliang Zhang, Li Medicine (Baltimore) Research Article Plasma brain natriuretic peptide (BNP), a diagnostic marker of cardiovascular diseases, has been previously linked to cerebrovascular diseases. Our goal was to determine whether plasma BNP level is helpful for identifying high-risk individuals who are likely to present with the 3 main subtypes of cerebral small vessel diseases (CSVDs), namely, white matter lesions, lacunar infarcts, and cerebral microbleeds, on magnetic resonance imaging (MRI) in patients with hypertension. Three hundred forty-six consecutive hypertensive patients presenting at our cardiology or neurology clinic were investigated. Plasma BNP level was measured by chemiluminescent microparticle immunoassay. The presence of CSVD was assessed by 1.5-T brain MRI. Multivariate linear regression was used to determine whether individual or combined MRI-defined CSVD subtypes were associated with BNP level, after adjustment for several covariates. The mean age of patients was 69.1 ± 9.8 years, and 44.2% were female. The highest quartile BNP group was positively associated with advanced age, female sex, clinically manifesting cardiac diseases, and ischemic CSVD (white matter lesions and lacunar infarcts) and no association with cerebral microbleeds. According to multivariate linear regression, white matter lesions [β = 0.722; 95% confidence interval (95% CI), 0.624–0.819] and lacunar infarcts (β = 0.635; 95% CI, 0.508–0.762) were independently associated with BNP level, even after controlling for vascular risk factors and clinically manifesting cardiac diseases. Combined white matter lesions and lacunar infarcts were more strongly associated with BNP level than each subtype alone. With the cutoff value of 106.4 pg/mL, BNP level had a sensitivity, a specificity, and an area under the curve of 95.2%, 64.9%, and 0.799, respectively, for white matter lesions, whereas the values were 143.0 pg/mL, 81.6%, 73.5%, and 0.848, respectively, for lacunar infarcts. Plasma BNP level, which is independently correlated with individual or combined white matter lesions and lacunar infarcts, is a useful molecular marker for identifying ischemic CSVD in patients with hypertension. Wolters Kluwer Health 2018-08-21 /pmc/articles/PMC6392776/ /pubmed/30170428 http://dx.doi.org/10.1097/MD.0000000000012088 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle Research Article
Wei, Weimin
Chen, Yan
Lei, Da
Zhang, Yanan
Weng, Xiuhong
Zhou, Yuliang
Zhang, Li
Plasma brain natriuretic peptide is a biomarker for screening ischemic cerebral small vessel disease in patients with hypertension
title Plasma brain natriuretic peptide is a biomarker for screening ischemic cerebral small vessel disease in patients with hypertension
title_full Plasma brain natriuretic peptide is a biomarker for screening ischemic cerebral small vessel disease in patients with hypertension
title_fullStr Plasma brain natriuretic peptide is a biomarker for screening ischemic cerebral small vessel disease in patients with hypertension
title_full_unstemmed Plasma brain natriuretic peptide is a biomarker for screening ischemic cerebral small vessel disease in patients with hypertension
title_short Plasma brain natriuretic peptide is a biomarker for screening ischemic cerebral small vessel disease in patients with hypertension
title_sort plasma brain natriuretic peptide is a biomarker for screening ischemic cerebral small vessel disease in patients with hypertension
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392776/
https://www.ncbi.nlm.nih.gov/pubmed/30170428
http://dx.doi.org/10.1097/MD.0000000000012088
work_keys_str_mv AT weiweimin plasmabrainnatriureticpeptideisabiomarkerforscreeningischemiccerebralsmallvesseldiseaseinpatientswithhypertension
AT chenyan plasmabrainnatriureticpeptideisabiomarkerforscreeningischemiccerebralsmallvesseldiseaseinpatientswithhypertension
AT leida plasmabrainnatriureticpeptideisabiomarkerforscreeningischemiccerebralsmallvesseldiseaseinpatientswithhypertension
AT zhangyanan plasmabrainnatriureticpeptideisabiomarkerforscreeningischemiccerebralsmallvesseldiseaseinpatientswithhypertension
AT wengxiuhong plasmabrainnatriureticpeptideisabiomarkerforscreeningischemiccerebralsmallvesseldiseaseinpatientswithhypertension
AT zhouyuliang plasmabrainnatriureticpeptideisabiomarkerforscreeningischemiccerebralsmallvesseldiseaseinpatientswithhypertension
AT zhangli plasmabrainnatriureticpeptideisabiomarkerforscreeningischemiccerebralsmallvesseldiseaseinpatientswithhypertension